Needling vs. microneedling plus light therapy for vitiligo
Part of Skin clinical trials.
This trial compares two types of needle treatments (needling and microneedling) combined with light therapy to see which works better for people with vitiligo that has lasted more than a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 15 and 60 years old
- You have had vitiligo for more than 1 year
- You do not have a history of keloids (raised, thick scars) or hypertrophic scarring
- You do not have a bleeding disorder, clotting problem, or take blood-thinning medications
- No active infection at the skin area to be treated
- You have not received any systemic (pill or injection) treatment for vitiligo in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gel made from stem-cell substances (secretome) given with narrow-band UVB light therapy for stable non-segmental vitiligo. It compares two ways of applying the gel to see which works better.
This trial tests whether a new combination treatment (microneedling plus a non-steroidal ointment called crisaborole) can help repigment patches of vitiligo that have been stable for a while. It is for people with non-segmental vitiligo that is not spreading.
This trial tests whether combining narrowband UVB light with topical steroids can help treat vitiligo, and looks at specific blood markers (CXCL11 and TEMRA) to see how the treatment affects the immune system. It may help patients with stable, non-segmental vitiligo who have not used systemic therapy in the last 3 months.
This trial tests whether adding a type of light therapy (narrow-band UVB) to a daily pill called ritlecitinib works better than the pill alone for treating vitiligo. It may help if you have non-segmental vitiligo covering a moderate amount of skin.
This trial tests a new injection called GR2301 combined with light therapy to treat vitiligo, a condition that causes loss of skin color. The study aims to see if this combination helps restore skin color and reduce white patches.
This study tests whether adding a pill called apremilast to narrowband UVB light therapy works better than light therapy alone for vitiligo. It may help repigment the skin more effectively.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.